13F-HR filed by Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC filed this 13F-HR for the quarter ended 2018-09-30, filed 2018-11-14, with 6 holding rows worth $440,629,000.
- Accession
- 0000950123-18-011520
- Filer
- CIK 1703031
- Filed
- 2018-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2018
A holdings report, 6 entries on the cover page, a total value of $440,629,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $440,629,000 with VALUE read as thousands by filing date, 13F file number 028-18477. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBain Capital Life Sciences Partners, LP 028-18476
- included managerBain Capital Life Sciences Fund, L.P. 028-18478
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| DICERNA PHARMACEUTICALS INC | 253031108 | COM | 8,930,237 | $136,275,000 | thousands by filing date | |
| SOLID BIOSCIENCES INC COM NEW | 83422E105 | Stock | 1,989,444 | $93,862,000 | thousands by filing date | |
| APTINYX INC | 03836N103 | COM | 2,225,092 | $64,439,000 | thousands by filing date | |
| Inflarx Nv | N44821101 | COM | 1,764,888 | $60,571,000 | thousands by filing date | |
| REPLIMUNE GROUP INC | 76029N106 | COMMON STOCK | 2,838,968 | $45,707,000 | thousands by filing date | |
| MARINUS PHARMACEUTICALS INC | 56854Q101 | COM | 3,977,453 | $39,775,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-18-011520 | this filing | 2018-11-14 | acceptance time not in the bulk data set |